well said redspeed! And to answer your question
Post# of 30028
(Total Views: 632)
Posted On: 12/15/2017 6:23:29 PM
well said redspeed!
And to answer your question:
the $160 million valuation was without ESS!
And like you said, we are talking about normal valuation let alone the potential of billions in the future!!
We have 3 great products/subsidiaries and yet we are still ridiculously undervalued to this day!
For ESS alone we paid more then what the company is currently valued lol!
The market will catch up eventually and the nay-sayers will probably be buying once the tender exchange is completed but by that time you would already have missed so much upside potential in pps (as you've already seen happening in the last 3 weeks).
Also take a closer look at the quote in their last PR.
At the time when i read that i thought to myself.... How are they going to do that when they have no money?
Seems to me they are moving forward anyway like they already have the money or else it wouldn't make sense to use those kind of wordings in the PR.
I wouldn't be surprised if we wake up to a nice funding PR in the very near term and if that happens that would really be life changing for the company and some of us
just my 2 cents.
And to answer your question:
the $160 million valuation was without ESS!
And like you said, we are talking about normal valuation let alone the potential of billions in the future!!
We have 3 great products/subsidiaries and yet we are still ridiculously undervalued to this day!
For ESS alone we paid more then what the company is currently valued lol!
The market will catch up eventually and the nay-sayers will probably be buying once the tender exchange is completed but by that time you would already have missed so much upside potential in pps (as you've already seen happening in the last 3 weeks).
Also take a closer look at the quote in their last PR.
Quote:
MANF Therapeutics is preparing to launch operations in 2018 for the purpose of re-initiating IND-enabling development towards first-in-man studies in an orphan ophthalmic indication.
At the time when i read that i thought to myself.... How are they going to do that when they have no money?
Seems to me they are moving forward anyway like they already have the money or else it wouldn't make sense to use those kind of wordings in the PR.
I wouldn't be surprised if we wake up to a nice funding PR in the very near term and if that happens that would really be life changing for the company and some of us
just my 2 cents.
(13)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼